42 results about "Platelet Numbers" patented technology

The present invention relates to compounds for treatment that protects the endothelium, prevent pathologic thrombus formation in the microcirculation and preserve platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and / or by agents modulating / preserving endothelial integrity and / or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death.

The present invention discloses the use of inhibitors and / or antagonists of PACAP signalling for the manufacture of a medicament for the prevention or treatment of decreased blood platelet numbers (thrombocytopenia).

The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and / or by agents modulating / preserving endothelial integrity and / or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death.

The present invention discloses the use of inhibitors and / or antagonists of PACAP signalling for the manufacture of a medicament for the prevention or treatment of decreased blood platelet numbers (thrombocytopenia).

The invention provides a novel application of a recombinant ganoderma lucidum immunological regulation protein (rLZ-8) in treating thrombopenia. In the experiments of preventing and treating the thrombopenia of rats and dogs caused by cyclophosphamide, the rLZ-8 prepared from physiological saline carries out administration on an experimental animal model with lower thrombocytes, THPO and IL-6 areused as positive medicines, continuous administration is carried out, the number of the thrombocytes in blood is detected, the changes of the number of the thrombocytes before and after therapy are contrasted, and the medicine effect is analyzed. Compared with a model group, the rLZ-8 medicine group already obviously stimulates the thrombocyte proliferation of rats, Guinea pigs and dogs in the initial period (the 3rd day to the 5th day) of the administration, the difference is very obvious, the thrombocytes are recovered to a normal level in the middle period (the 7th day to the 10th day) of the administration, and the invention also obtains a very good effect in treating the thrombopenia of a Guinea pig experimental animal model caused by injecting anti-thrombocyte serum.

The invention discloses perfluorocarbon albumin nanoparticles which comprise albumins and perfluorocarbon compounds, wherein the albumins coat the perfluorocarbon compounds, and the mass ratio of theperfluorocarbon compounds to the albumins is (4-40): 1. The perfluorocarbon albumin nanoparticles have good biological safety as a novel blood platelet inhibitor. The perfluorocarbon albumin nanoparticles which are administrated will induce great reduction of quantity of blood platelets in a human body, various functions of the blood platelets can be also inhibited obviously, and the perfluorocarbon albumin nanoparticles have relatively good clinical applications and practical treatment meaning.

The present invention aims to provide a hollow fiber membrane module capable of producing washed platelets having a low total protein amount and a high total platelet count from a platelet suspension. The present invention provides a hollow fiber membrane module for washing platelets by removal of impurities from a platelet suspension, comprising: a housing having a platelet suspension inlet, washed platelet outlet, and filtrate outlet; and a hollow fiber membrane for filtering the platelet suspension, wherein pores through which the platelets do not pass, while the impurities pass, are formed, which hollow fiber membrane is arranged inside the housing; wherein the capacity of the inlet-side space which communicates with the platelet suspension inlet and stores the platelet suspension before being filtered through the hollow fiber membrane in the housing is 30 to 400 mL, and the module water permeability is 50 to 300 mL / Pa / hr.